ACRS - アクラリス・セラピュ―ティクス （Aclaris Therapeutics Inc.） アクラリス・セラピュ―ティクスACRSのチャート
ACRSの企業情報
| symbol | ACRS |
|---|---|
| 会社名 | Aclaris Therapeutics Inc （アクラリス・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アクラリス・セラピュティクス(Aclaris Therapeutics Inc.)は皮膚科学者主導のバイオ医薬品会社である。同社は皮膚科兆候の治療のために差別化された薬物の特定・開発・商業化に従事する。また、炎症性疾患、免疫学的疾患および癌を治療するためのキナーゼ阻害剤の発見・開発を行う。同社の創薬プラットフォームKINect技術は、キナーゼに焦点を当てた薬物探索エンジンである。そのKINectは、独自の化合物コレクションを統合するために計算化学を利用し、潜在的な候補者を同定して前臨床・臨床開発に進めるために高度に経験豊富な生物学者と薬化学者より協力を貰える。 アクラリス・セラピュ―ティクスは米国の専門医薬品企業。臨床段階で、皮膚疾患に対する局所用薬剤の開発、商業化に従事。主要な薬剤候補「A-101」は高濃度過酸化水素ベ―スで、脂漏性角化症や良性皮膚腫瘍の治療に利用される。同社は「A-101」の臨床試験を3件完了し、顔面や腹部の腫瘍治療に効果を上げる。本社はペンシルベニア州マルバ―ン。 Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. |
| 本社所在地 | 640 Lee Road Suite 200 Wayne PA 19087 USA |
| 代表者氏名 | Stephen A. Tullman スティーブン・A・Tullman |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 484-324-7933 |
| 設立年月日 | 41091 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 96人 |
| url | www.aclaristx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/acrs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -106.29000 |
| 終値（lastsale） | 13.26 |
| 時価総額（marketcap） | 410803591.38 |
| 時価総額 | 時価総額（百万ドル） 405.53690 |
| 売上高 | 売上高（百万ドル） 6.47700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 241.48490 |
| 当期純利益 | 当期純利益（百万ドル） -104.41000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aclaris Therapeutics Inc revenues increased from $0K to $4.8M. Net loss increased from $27.4M to $61.4M. Revenues reflect Revenue increase from $0K to $1.1M. Higher net loss reflects Research and Development - gross increase of 82% to $24.1M (expense) General and Administrative - gross increase of 14% to $9.8M (expense) Stock-based Compensation in R&D increase of 38% to $3.5M (expense). |
ACRSのテクニカル分析
ACRSのニュース
Aclaris Therapeutics Provides 2023 Outlook 2023/01/06 12:01:00 GlobeNewswire
WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today is providing a corporate outlook for 2023.
Other news to note for Dec. 6, 2022 2022/12/06 17:00:00 BioWorld
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aclaris, Astellas, Biocon, CMS Aesthetics, Cosmo, ERS Genomics, Focus-X, Full-Life Technologies, Immutep, Incyte, Legochem, Merck KGaA, Pediatrix, Pfizer, Sirona, Sotio, Viatris, Wanbang.
Looking Into Aclaris Therapeutics''s Return On Capital Employed 2022/12/05 14:45:56 Benzinga
According to Benzinga Pro data, during Q3, Aclaris Therapeutics (NASDAQ: ACRS ) posted sales of $19.02 million. Earnings were up 2.82%, but Aclaris Therapeutics still reported an overall loss of $19.95 million. Aclaris Therapeutics collected $1.53 million in revenue during Q2, but reported earnings showed a $20.53 million loss. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com
Goldman Sachs initiates Aclaris at Buy citing potential in lead asset (NASDAQ:ACRX) 2022/12/01 19:23:18 Seeking Alpha
Aclaris Therapeutics (ACRX), a biopharma focused on immune-inflammatory diseases, ticked higher on Thursday after Goldman Sachs launched its coverage with a Buy recommendation and a $25…
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China 2022/11/29 12:00:00 GlobeNewswire
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic company, today announced that the companies have entered into a license agreement. Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris’ investigational “soft” Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan). Aclaris will retain the rights to develop, manufacture and commercialize ATI-1777 in the rest of the world.
Other news to note for Dec. 6, 2022 2022/12/06 17:00:00 BioWorld
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aclaris, Astellas, Biocon, CMS Aesthetics, Cosmo, ERS Genomics, Focus-X, Full-Life Technologies, Immutep, Incyte, Legochem, Merck KGaA, Pediatrix, Pfizer, Sirona, Sotio, Viatris, Wanbang.
Looking Into Aclaris Therapeutics''s Return On Capital Employed 2022/12/05 14:45:56 Benzinga
According to Benzinga Pro data, during Q3, Aclaris Therapeutics (NASDAQ: ACRS ) posted sales of $19.02 million. Earnings were up 2.82%, but Aclaris Therapeutics still reported an overall loss of $19.95 million. Aclaris Therapeutics collected $1.53 million in revenue during Q2, but reported earnings showed a $20.53 million loss. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com
Goldman Sachs initiates Aclaris at Buy citing potential in lead asset (NASDAQ:ACRX) 2022/12/01 19:23:18 Seeking Alpha
Aclaris Therapeutics (ACRX), a biopharma focused on immune-inflammatory diseases, ticked higher on Thursday after Goldman Sachs launched its coverage with a Buy recommendation and a $25…
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China 2022/11/29 12:00:00 GlobeNewswire
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic company, today announced that the companies have entered into a license agreement. Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris’ investigational “soft” Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan). Aclaris will retain the rights to develop, manufacture and commercialize ATI-1777 in the rest of the world.
Aclaris Therapeutics names CEO as board chair, COO to take helm 2022/11/22 21:09:15 Seeking Alpha
Aclaris Therapeutics (ACRS) said Tuesday co-founder and current CEO Neal Walker will transition to the role of board chair, effective Jan
Other news to note for Dec. 6, 2022 2022/12/06 17:00:00 BioWorld
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Aclaris, Astellas, Biocon, CMS Aesthetics, Cosmo, ERS Genomics, Focus-X, Full-Life Technologies, Immutep, Incyte, Legochem, Merck KGaA, Pediatrix, Pfizer, Sirona, Sotio, Viatris, Wanbang.
Looking Into Aclaris Therapeutics''s Return On Capital Employed 2022/12/05 14:45:56 Benzinga
According to Benzinga Pro data, during Q3, Aclaris Therapeutics (NASDAQ: ACRS ) posted sales of $19.02 million. Earnings were up 2.82%, but Aclaris Therapeutics still reported an overall loss of $19.95 million. Aclaris Therapeutics collected $1.53 million in revenue during Q2, but reported earnings showed a $20.53 million loss. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com
Goldman Sachs initiates Aclaris at Buy citing potential in lead asset (NASDAQ:ACRX) 2022/12/01 19:23:18 Seeking Alpha
Aclaris Therapeutics (ACRX), a biopharma focused on immune-inflammatory diseases, ticked higher on Thursday after Goldman Sachs launched its coverage with a Buy recommendation and a $25…
Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China 2022/11/29 12:00:00 GlobeNewswire
WAYNE, Pa. and SHANGHAI, China, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, and Pediatrix Therapeutics, Inc. (Pediatrix), a pediatrics-focused therapeutic company, today announced that the companies have entered into a license agreement. Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris’ investigational “soft” Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan). Aclaris will retain the rights to develop, manufacture and commercialize ATI-1777 in the rest of the world.